Latest stories
Featured
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...
Press Release, Business Development 12 February 2024
- Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US Press Release, Product 27 February 2025 Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US
- Strong 2024 performance and a positive outlook for 2025 Press Release, Financial Results 26 February 2025 Strong 2024 performance and a positive outlook for 2025
- Notice of results Press Release, Financial Results 10 February 2025 Notice of results
- Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE Press Release, Business Development 30 January 2025 Hikma and M42 sign strategic MOU to advance healthcare innovation in the UAE
Related content